Patrick Heron has served as a member of the Board since November 2018. Mr. Heron is a General Partner with Frazier Life Sciences ( Frazier ), a private equity and venture capital firm, a position he has held since September 1999. Mr. Heron has been active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc. and Silvergate. Prior to joining Frazier, Mr. Heron helped develop McKinsey & Co. s west coast biotechnology consulting practice. Mr. Heron currently serves on the board of directors of Arcutis Biotherapeutics, Inc. and MBX Biosciences, Inc., both public biopharmaceutical companies, as well as private companies Alpha-9 Oncology, Inc., Alceptor Therapeutics, Inc., Bluewater Biosciences, Inc., Tubulis GmbH and Breakwater Therapeutics. Mr. Heron previously served on the boards of directors of public biopharmaceutical companies Imago Biosciences, Inc. from 2014 until 2022, Vaxcyte, Inc. from 2017 until 2021, Iterum Therapeutics plc from 2016 until 2021, Passage Bio, Inc. from 2018 until 2021 and HilleVax, Inc. from 2021 to 2025. Mr. Heron also previously served on the board of directors of privately held Scout Bio, Inc. from 2018 until 2023. Mr. Heron received his B.A. in Political Science from the University of North Carolina at Chapel Hill and an MBA from Harvard Business School. Skills and Qualifications specific to Mirum Pharmaceuticals, Inc.: The Board and Nominating Committee believe that Mr. Heron s extensive business background and his experience in venture capital and the life science industry qualifies him to serve on the Board.